Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

Share Price is delayed by 15 minutes
Get Live Data
2,080.00    -62.00 (-2.89%)
Bid:
2,066.00
Ask:
2,070.00
Spread: 4.00 (0.194%)
Market Cap: £3.48b
JMAT Live PriceLast checked at - London Stock Exchange

Intraday Johnson Matthey Share Chart

Johnson Matthey business update

7 Feb 2018 07:00

RNS Number : 0785E
Johnson Matthey PLC
07 February 2018
 

Johnson Matthey business update

 

Johnson Matthey today provides an update on two business matters: the settlement of the contract dispute lawsuit reported as a contingent liability in November 2017; and the positive impact of US tax legislation on the group.

Settlement of after treatment contract lawsuit

As announced on 21st November 2017, a group company, Johnson Matthey Inc. (JMI), had been made a defendant to a contract dispute lawsuit alongside a supplier to an automotive OEM in the United States. The dispute related to a component supplied by the group. We reported a contingent liability in relation to the lawsuit in the announcement of our half year results for the six months ended 30th September 2017.

 

Today we announce that the lawsuit against JMI has been settled on mutually acceptable terms with no admission of fault. Under this settlement agreement, Johnson Matthey will recognise a charge of £50 million in connection with resolution of the lawsuit. This charge will be excluded from underlying operating profit for the year ending 31st March 2018.

 

Positive impact of US tax legislation on Johnson Matthey

We note the approval of the US Tax Cuts and Jobs Act, which became generally effective 1st January 2018, and expect to be positively impacted by these changes.

 

The lowering of the US corporate tax rate leads to a revaluation of our US deferred tax liabilities, which we estimate will result in a £30 million one-off non-cash benefit in the income tax expense line in the income statement for the year ending 31st March 2018. This will be excluded from the tax on underlying profit.

 

For the current financial year to 31st March 2018, we anticipate no change to the effective tax rate on underlying profit. We continue to expect this to be around 18%. Looking forward to the financial year ending 31st March 2019 and beyond we expect these changes will reduce the effective tax rate on underlying profit by around two percentage points. We continue to work through the full impact and will give more detail in our preliminary announcement for the year ending 31st March 2018.

 

Outlook

Our outlook for the year ending 31st March 2018 remains unchanged.

 

Enquiries:

Analysts and investors:

Martin Dunwoodie +44 (0)20 7269 8241

Simon McGough +44 (0)20 7269 8235

Katharine Burrow +44 (0)20 7269 8444

Media:

Sally Jones +44 (0)20 7269 8407

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDTFMJTMBAMBIP
Date   Source Headline
3rd Jun 20269:03 amRNSDirector/PDMR Shareholding
2nd Jun 20264:40 pmRNSDirector/PDMR Shareholding
1st Jun 20264:02 pmRNSHolding(s) in Company
28th May 20267:05 amRNSBoard Changes
28th May 20267:01 amRNSJohnson Matthey acquisition of Cormetech
28th May 20267:00 amRNSJohnson Matthey Full Year Results
14th May 202611:42 amRNSDirector/PDMR Shareholding
16th Apr 202611:51 amRNSDirector/PDMR Shareholding
24th Mar 202611:30 amRNSDirector/PDMR Shareholding
27th Feb 20267:00 amRNSDirector Declaration
24th Feb 20263:30 pmRNSDirector/PDMR Shareholding
24th Feb 20269:48 amRNSDirector/PDMR Shareholding
23rd Feb 20265:19 pmRNSDirector/PDMR Shareholding
23rd Feb 20267:00 amRNSUpdate on Catalyst Technologies sale
12th Feb 202612:44 pmRNSDirector/PDMR Shareholding
14th Jan 20262:22 pmRNSDirector/PDMR Shareholding
8th Jan 202610:01 amRNSHolding(s) in Company
30th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
11th Dec 20254:51 pmRNSDirector/PDMR Shareholding
20th Nov 20257:00 amRNSDirectorate change
20th Nov 20257:00 amRNSJohnson Matthey Half Year Results
13th Nov 20257:00 amRNSDirector/PDMR Shareholding
24th Oct 202511:29 amRNSHolding(s) in Company
21st Oct 20253:44 pmRNSHolding(s) in Company
13th Oct 202511:55 amRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSFinancial reporting structure and trading update
3rd Oct 202510:23 amRNSHolding(s) in Company
30th Sep 20257:00 amRNSHolding(s) in Company
26th Sep 20255:29 pmRNSHolding(s) in Company
17th Sep 20259:00 amRNSDirector Declaration
15th Sep 20252:37 pmRNSHolding(s) in Company
11th Sep 20254:13 pmRNSDirector/PDMR Shareholding
8th Sep 20256:00 pmRNSHolding(s) in Company
4th Sep 20255:19 pmRNSHolding(s) in Company
2nd Sep 20254:07 pmRNSHolding(s) in Company
29th Aug 202512:05 pmRNSTotal Voting Rights
26th Aug 20252:07 pmRNSDirector/PDMR Shareholding
13th Aug 20254:38 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
5th Aug 20255:19 pmRNSHolding(s) in Company
5th Aug 20254:50 pmRNSDirector/PDMR Shareholding
25th Jul 20252:12 pmRNSHolding(s) in Company
23rd Jul 20252:23 pmRNSHolding(s) in Company
18th Jul 202512:07 pmRNSDirector/PDMR Shareholding
18th Jul 20259:18 amRNSHolding(s) in Company
17th Jul 20252:20 pmRNSResult of AGM
17th Jul 20257:00 amRNSAppointment of Andrew Cosslett as Chair
9th Jul 20254:48 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.